An official website of the United States government
ACIP Presentation Slides: June 26-28, 2024 Meeting
Note: These files are not yet 508
Slides will be added as they become available.
June 26, 2024
Welcome & Introductions
- Introduction
Dr. K Talbot, Dr. M Wharton
Respiratory Syncytial Virus Vaccines – Adult
- Introduction [10 pages]
Dr. C Kotton - Abrysvo (Pfizer) safety and immunogenicity in non-pregnant adults aged 18-59 years [23 pages]
Dr. I Munjal - Arexvy (GSK) immunogenicity with a 24-month revaccination interval [18 pages]
Dr. S Gerber - mRNA-1345 (Moderna) Update on vaccine safety, efficacy and revaccination data [24 pages]
Dr. R Das - Postmarketing safety updates: Vaccine Safety Datalink [28 pages]
Dr. J Donahue - Evaluation of Guillain-Barre Syndrome (GBS) following RSV vaccination among adults 65 years and older [19 pages]
Dr. P Lloyd - Observational RSV vaccine effectiveness [43 pages]
Dr. D Surie - Economic analysis of adult RSV vaccination [40 pages]
Dr. D Hutton - Update to benefits and risks discussion [29 pages]
Dr. D Hutton - Comparison of economic analyses of adult RSV vaccination [20 pages]
Dr. I Ortega-Sanchez - Evidence to Recommendations [102 pages]
Dr. M Melgar, L Roper, Dr. A Britton - Clinical Considerations [13 pages]
Dr. M Melgar
Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®)
- Introduction [6 pages]
Dr. J Loehr - EtR and proposed recommendations: Use of Vaxelis among American Indian and Alaska Native Infants [53 pages]
Dr. J Collins
Chikungunya Vaccine
- Introduction [7 pages]
Dr. W Chen - Update on chikungunya vaccines [3 pages]
Dr. S Hills - Epidemiology of chikungunya in U.S. territories and states [31 pages]
Dr. S Hills - Cost-effectiveness of use of live attenuated chikungunya vaccine among adults living in U.S. territories [32 pages]
Dr. K Kilburn, Dr. E Staples - Next steps for Work Group [4 pages]
Dr. S Hills
Dengue Vaccines
- Dengvaxia discontinuation [4 pages]
Dr. N Bergren - Dengue vaccine updates [22 pages]
Dr. J Wong
June 27, 2024
Welcome & Introductions
- Introduction
Dr. K Talbot, Dr. M Wharton
COVID-19 Vaccine
- Introduction [10 pages]
Dr. M Daley - COVID-19-associated hospitalizations [24 pages]
Dr. F Havers - COVID-19 vaccine effectiveness update [30 pages]
Dr. R Link-Gelles - Vaccine safety update for 2023-2024 COVID-19 vaccine [41 pages]
Dr. J Duffy - Economic analysis of COVID-19 vaccination [38 pages]
Dr. L Prosser - EtR for use of the 2024-2025 COVID-19 vaccine [131 pages]
Dr. L Panagiotakopoulos - COVID-19 vaccine implementation [28 pages]
Dr. S Stokley
Influenza Vaccines
- Introduction [6 pages]
Dr. J Loehr - Influenza A (H5N1) Update [16 pages]
Dr. V Dugan - WG Considerations and Proposed Recommendations [50 pages]
Dr. L Grohskopf
Pneumococcal Vaccines
- Introduction [14 pages]
Dr. J Loehr - Economic analysis and public health impact of PCV21 use in adults [45 pages]
Mr. C Stoecker - Comparison of economic analysis on PCV21 use in adults [21 pages]
Dr. A Leidner - Summary of WG Interpretation of EtR and policy options on PCV21 use in adults and clinical guidance for implementation [55 pages]
Dr. M Kobayashi
June 28, 2024
Welcome & Introductions
- Introduction
Dr. K Talbot, Dr. M Wharton
Meningococcal Vaccines
- Introduction [6 pages]
Dr. J Loehr - Epidemiology Updates [51 pages]
Ms. A Rubis - GSK Pentavalent Vaccine Immunogenicity and Safety [23 pages]
Dr. W Sohn - WG Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination [32 pages]
Dr. S Schillie
Respiratory Syncytial Virus Vaccines – Maternal/Pediatric
- Introduction [9 pages]
Dr. S Long - Implementation and uptake of nirsevimab and maternal RSV vaccine [18 pages]
Dr. S Stokley - Maternal RSV vaccine safety surveillance [28 pages]
Dr. P Moro - Summary of effectiveness of nirsevimab in infants [32 pages]
Dr. A Payne - Work Group considerations [20 pages]
Dr. J Jones, Dr. K Fleming-Dutra